Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day : An analysis using continuous glucose monitoring
(2017) In Diabetes/Metabolism Research and Reviews 33(4).- Abstract
Background: In the parent study of this analysis, patients with type 2 diabetes received lixisenatide before breakfast or the main meal of the day. This substudy was designed to examine the effect of lixisenatide administered before breakfast or the main meal of the day on continuously assessed 24-hour patient glucose profiles. Methods: A subset of patients from the parent study underwent 2 14-day periods of continuous glucose monitoring (CGM) at the start and end of the 24-week study. Ambulatory glucose profile analysis was used to measure changes over time in detailed aspects of the glucose profiles. The breakfast group consumed a standardized meal during both CGM periods to determine change in 4-hour glycemic response. Results: Data... (More)
Background: In the parent study of this analysis, patients with type 2 diabetes received lixisenatide before breakfast or the main meal of the day. This substudy was designed to examine the effect of lixisenatide administered before breakfast or the main meal of the day on continuously assessed 24-hour patient glucose profiles. Methods: A subset of patients from the parent study underwent 2 14-day periods of continuous glucose monitoring (CGM) at the start and end of the 24-week study. Ambulatory glucose profile analysis was used to measure changes over time in detailed aspects of the glucose profiles. The breakfast group consumed a standardized meal during both CGM periods to determine change in 4-hour glycemic response. Results: Data were available for 69 patients in the substudy, 40 from the original breakfast group and 29 from the main meal group. Between baseline and end of study, mean (standard deviation) total glucose exposure decreased from 4198.1 (652.3) to 3681.2 (699.6) mg/dL*24 h in the breakfast group (P < .0001) and from 4127.9 (876.8) to 3880.9 (1165.0) mg/dL*24 h in the main meal group (P = .0224). For patients included in the substudy, HbA1c decreased by approximately 0.6% in both groups. Mean (standard deviation) 4-hour total glucose exposure fell by 168.9 (158.4) mg/dL*4 h (P < .0001) from baseline. Conclusions: This analysis demonstrates that lixisenatide has beneficial effects on components of the 24-hour glucose profile, which endure beyond the meal at which it is administered. Continuous glucose monitoring analysis detects changes not captured using HbA1c alone.
(Less)
- author
- Bergenstal, Richard M. ; Strock, Ellie ; Mazze, Roger ; Powers, Margaret A. ; Monk, Arlene M. ; Richter, Sara ; Souhami, Elisabeth and Ahrén, Bo LU
- organization
- publishing date
- 2017
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Continuous glucose monitoring, Glucagon-like peptide-1, Glycated hemoglobin, Postprandial plasma glucose, Type 2 diabetes
- in
- Diabetes/Metabolism Research and Reviews
- volume
- 33
- issue
- 4
- article number
- e2879
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- scopus:85014227074
- pmid:28032465
- wos:000400581600012
- ISSN
- 1520-7552
- DOI
- 10.1002/dmrr.2879
- language
- English
- LU publication?
- yes
- id
- 49892aed-fcb8-4bff-90a5-f03b872944fe
- date added to LUP
- 2017-03-16 08:27:04
- date last changed
- 2024-10-14 02:37:03
@article{49892aed-fcb8-4bff-90a5-f03b872944fe,
abstract = {{<p>Background: In the parent study of this analysis, patients with type 2 diabetes received lixisenatide before breakfast or the main meal of the day. This substudy was designed to examine the effect of lixisenatide administered before breakfast or the main meal of the day on continuously assessed 24-hour patient glucose profiles. Methods: A subset of patients from the parent study underwent 2 14-day periods of continuous glucose monitoring (CGM) at the start and end of the 24-week study. Ambulatory glucose profile analysis was used to measure changes over time in detailed aspects of the glucose profiles. The breakfast group consumed a standardized meal during both CGM periods to determine change in 4-hour glycemic response. Results: Data were available for 69 patients in the substudy, 40 from the original breakfast group and 29 from the main meal group. Between baseline and end of study, mean (standard deviation) total glucose exposure decreased from 4198.1 (652.3) to 3681.2 (699.6) mg/dL*24 h in the breakfast group (P < .0001) and from 4127.9 (876.8) to 3880.9 (1165.0) mg/dL*24 h in the main meal group (P = .0224). For patients included in the substudy, HbA<sub>1c</sub> decreased by approximately 0.6% in both groups. Mean (standard deviation) 4-hour total glucose exposure fell by 168.9 (158.4) mg/dL*4 h (P < .0001) from baseline. Conclusions: This analysis demonstrates that lixisenatide has beneficial effects on components of the 24-hour glucose profile, which endure beyond the meal at which it is administered. Continuous glucose monitoring analysis detects changes not captured using HbA<sub>1c</sub> alone.</p>}},
author = {{Bergenstal, Richard M. and Strock, Ellie and Mazze, Roger and Powers, Margaret A. and Monk, Arlene M. and Richter, Sara and Souhami, Elisabeth and Ahrén, Bo}},
issn = {{1520-7552}},
keywords = {{Continuous glucose monitoring; Glucagon-like peptide-1; Glycated hemoglobin; Postprandial plasma glucose; Type 2 diabetes}},
language = {{eng}},
number = {{4}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Diabetes/Metabolism Research and Reviews}},
title = {{Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day : An analysis using continuous glucose monitoring}},
url = {{http://dx.doi.org/10.1002/dmrr.2879}},
doi = {{10.1002/dmrr.2879}},
volume = {{33}},
year = {{2017}},
}